You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK)擬於中國江蘇蘇州蘇州工業園區總部建造全球研發中心
格隆匯 12-31 22:34

格隆匯12月31日丨東曜藥業-B(01875.HK)公吿,於2021年12月31日,蘇州東曜(為公司全資附屬公司)與上海寶冶訂立建造協議,內容有關集團於中國江蘇省蘇州市蘇州工業園區總部建造全球研發中心,建造工程合約總金額為人民幣8350萬元。

全球研發中心乃集團開展日常業務自用,將具備早期研發、工藝開發、質量研究以及總部辦公等功能。全球研發中心建成將有利於鞏固本集團在生物創新醫藥領域的發展優勢,實現研發與生產區域無縫連接,加強本集團在中國以至全球各地的創新藥品研發及合作。

全球研發中心總建築面積約25,000平方米。其中,研發核心實驗區域能夠同時開展多個單克隆抗體(mAb)藥物、抗體偶聯藥物(ADC)、溶瘤病毒藥物及特殊小分子抗腫瘤藥物的研究和工藝開發等實驗。建設主體預計於2023年完工,項目擬投資總額約為人民幣1.80億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account